HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …

Osteosarcoma, with poor survival after metastasis, is considered the most common primary
bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival …

There is considerable potential for integrating transarterial chemoembolization (TACE),
programmed death-(ligand) 1 (PD-[L] 1) inhibitors, and molecular targeted treatments (MTT) …

Background Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced
hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a …

Immunogenic cell death (ICD) is a regulated form of cell death that induces the activation of
both innate and adaptive immune responses through the release of damage-associated …

Hepatocellular carcinoma (HCC) accounts for 90% of liver tumours and is one of the leading
causes of mortality. Cirrhosis due to viral hepatitis, alcohol or steatohepatitis is the major risk …

Objectives This study aimed to investigate the efficacy and safety of transarterial
chemoembolization (TACE) plus camrelizumab, a monoclonal antibody targeting …

Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical
outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental …

Immunotherapy has remarkably revolutionized the management of advanced HCC and
prompted clinical trials, with therapeutic agents being used to selectively target immune cells …

Liver cancer is the third leading cause of cancer-related death worldwide with primary type
hepatocellular carcinoma (HCC). Factors, including carcinogens, infection of hepatitis …